Christopher Horan Sells 7,002 Shares of Artiva Biotherapeutics (NASDAQ:ARTV) Stock

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) insider Christopher Horan sold 7,002 shares of the firm’s stock in a transaction on Tuesday, May 19th. The shares were sold at an average price of $9.01, for a total value of $63,088.02. Following the completion of the sale, the insider owned 293,450 shares of the company’s stock, valued at approximately $2,643,984.50. This trade represents a 2.33% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Artiva Biotherapeutics Stock Performance

Shares of NASDAQ:ARTV opened at $7.84 on Thursday. Artiva Biotherapeutics, Inc. has a twelve month low of $1.47 and a twelve month high of $14.53. The firm has a market cap of $193.80 million, a PE ratio of -2.21 and a beta of 2.86. The business has a fifty day moving average of $8.36 and a 200-day moving average of $5.67.

Artiva Biotherapeutics (NASDAQ:ARTV) last announced its earnings results on Friday, May 8th. The company reported ($0.95) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.07). On average, analysts anticipate that Artiva Biotherapeutics, Inc. will post -2.45 EPS for the current fiscal year.

Trending Headlines about Artiva Biotherapeutics

Here are the key news stories impacting Artiva Biotherapeutics this week:

• Positive Sentiment: Artiva announced multiple AlloNK® data presentations for the upcoming EULAR 2026 Congress, including a late-breaking oral presentation highlighting clinical efficacy comparable to autologous CAR T-cell therapy in rheumatologic diseases. Article Title
• Positive Sentiment: The company appointed veteran biotech executive Diego Miralles, M.D., as President and Head of Research and Development, which could strengthen leadership and development execution. Article Title
• Neutral Sentiment: Artiva disclosed several insider sales by CEO Fred Aslan, COO Jennifer Bush, SVP Heather Raymon, and insider Christopher Horan/ Subhashis Banerjee at $9.01 per share; the company said these were primarily for tax withholding related to equity vesting, which makes them less alarming than open-market selling. Article Title
• Neutral Sentiment: Recent analyst commentary remains constructive overall, with multiple firms raising price targets sharply, but the stock also faces skepticism from some ratings changes and a still-loss-making earnings profile.
• Negative Sentiment: The company recently reported a quarterly loss of $0.95 per share, wider than expectations, reinforcing concerns about ongoing losses and execution risk.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on ARTV shares. HC Wainwright raised their target price on Artiva Biotherapeutics from $15.00 to $35.00 and gave the company a “buy” rating in a research note on Friday, May 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research note on Friday, April 24th. Wedbush lifted their price objective on Artiva Biotherapeutics from $23.00 to $40.00 and gave the stock an “outperform” rating in a research report on Monday, May 11th. Cantor Fitzgerald lifted their price objective on Artiva Biotherapeutics from $10.00 to $40.00 and gave the stock an “overweight” rating in a research report on Monday, May 11th. Finally, Wall Street Zen lowered Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Sunday. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $39.00.

Institutional Trading of Artiva Biotherapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Marshall Wace LLP acquired a new stake in Artiva Biotherapeutics in the fourth quarter worth about $341,000. Jane Street Group LLC acquired a new stake in Artiva Biotherapeutics in the fourth quarter worth about $174,000. Landscape Capital Management L.L.C. acquired a new stake in Artiva Biotherapeutics in the third quarter worth about $112,000. BNP Paribas Financial Markets increased its position in Artiva Biotherapeutics by 14,463.5% in the third quarter. BNP Paribas Financial Markets now owns 118,547 shares of the company’s stock worth $340,000 after purchasing an additional 117,733 shares during the period. Finally, Qube Research & Technologies Ltd acquired a new stake in Artiva Biotherapeutics in the second quarter worth about $58,000.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.